

ACTIVE CLINICAL TRIAL IN UROTHELIAL CANCER



PHASE 2 (NCT03785925)

PIVOT-10: Bempegaldesleukin with nivolumab in patients with advanced urothelial cancer

A single-arm study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) in cisplatin-ineligible, locally advanced or metastatic urothelial cancer¹

Scan here to find out more about this clinical study at ClinicalTrials.gov



POPULATION

- Untreated metastatic or unresectable urothelial cancer
- Ineligible for cisplatin
- Any PD-L1 status

N=192



BEMPEG + NIVO

PRIMARY ENDPOINT

- ORR (in patients with PD-L1 low tumors)^a

SECONDARY ENDPOINTS

- ORR and DOR^{a,b}
- Safety and tolerability

Bempegaldesleukin is an investigational CD122-preferential IL-2-pathway agonist²

Nivolumab is a PD-1 blocking antibody³

^aAssessed by blinded independent central review

^bORR in all treated patients and DOR in all treated patients and patients whose tumors have low PD-L1 expression

BEMPEG, bempegaldesleukin (NKTR-214); DOR, duration of response; NIVO, nivolumab; ORR, objective response rate; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.

1. ClinicalTrials.gov. NCT03785925. <https://clinicaltrials.gov/ct2/show/NCT03785925>. Accessed March 29, 2021; 2. Bentebibel SE, et al. *Cancer Discov* 2019;9:711-21; 3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: January 2021).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



^aNeoadjuvant and adjuvant setting.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; R/R, relapsed/refractory

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2021. All rights reserved.